Publications by authors named "Pamela M Moye-Dickerson"
Background: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS), a type of liver injury, has not been reported with this therapy.
Case Presentation: We report the case of a 48-year-old male with HIV and VBDS secondary to antiretroviral therapy.